Board Member
Denali Therapeutics Inc. (DNLI)Equibles does not estimate personal net worth.
Get an email with a short summary when Denali Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get DNLI alertsRyan J. Watts is recorded as Board Member at Denali Therapeutics Inc. (DNLI) since January 1, 2015 and CEO at Denali Therapeutics Inc. (DNLI). The newest filing on record that lists Ryan J. Watts as CEO and Board Member at Denali Therapeutics Inc. (DNLI) is dated April 21, 2026. The proxy statement of Denali Therapeutics Inc. reports total compensation of $4,751,515 for Ryan J. Watts in fiscal 2025, including a base salary of $718,000. Disclosed compensation is on record for 9 fiscal years. Ryan J. Watts has spoken on 3 earnings calls and 3 other investor events across 1 company, most recently for Denali Therapeutics Inc. on November 3, 2026. Denali Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Denali Therapeutics Inc. includes Alexander Schuth (CFO), Steve E. Krognes (CFO and Board Member), Alexander O. Schuth (COO) and 7 others.
“This was the defining quarter for Denali, and we are excited to share it with you. I want to start where we always do, with our purpose, transforming life for people living with serious disease.”
“Yeah, I mean, I think that it's a great question, and it's a relevant question, And it's a question that we ask in really two levels. One is a biotech community, and specifically here in the U.S., how do we view China from a competitive perspective?”
“This was a transformative quarter for Denali. We completed the first full quarter of the Ablea launch, advanced two transport vehicle-enabled Alzheimer's disease programs into clinical development, and further strengthened our financial position.”
“Maybe before I talk about the future, I'll just have a comment or two about the past. We've been working on blood-brain barrier technologies for almost exactly 20 years.”
“We're going to get started on our next session. I'm Andrew Tsai, senior biotech analyst at Jeffries.”
2015-01-01–present
Last confirmed April 21, 2026
Start not stated–present
Last confirmed April 21, 2026
Biotechnology · Healthcare
CEO, Board Member
2015-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $718,000 | $4,751,515 |
| 2024 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $690,100 | $6,557,662 |
| 2023 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $670,000 | $7,879,267 |
| 2022 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $645,000 | $9,284,688 |
| 2021 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $610,104 | $12,673,479 |
| 2020 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $589,472 | $9,302,445 |
| 2019 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $566,800 | $4,978,607 |
| 2018 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $545,000 | $5,983,923 |
| 2017 | Denali Therapeutics Inc. (DNLI) | President and Chief Executive Officer | $481,056 | $1,366,863 |
